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Abstract
Background: Oxidative stress plays a role in acute and chronic inflammatory disease and antioxidant supplementation 
has demonstrated beneficial effects in the treatment of these conditions. This study was designed to determine the 
optimal dose of an antioxidant supplement in healthy volunteers to inform a Phase 3 clinical trial.
Methods: The study was designed as a combined Phase 1 and 2 open label, forced titration dose response study in 
healthy volunteers (n = 21) to determine both acute safety and efficacy. Participants received a dietary supplement in a 
forced titration over five weeks commencing with a no treatment baseline through 1, 2, 4 and 8 capsules. The primary 
outcome measurement was ex vivo changes in serum oxygen radical absorbance capacity (ORAC). The secondary 
outcome measures were undertaken as an exploratory investigation of immune function.
Results: A significant increase in antioxidant activity (serum ORAC) was observed between baseline (no capsules) and 
the highest dose of 8 capsules per day (p = 0.040) representing a change of 36.6%. A quadratic function for dose levels 
was fitted in order to estimate a dose response curve for estimating the optimal dose. The quadratic component of the 
curve was significant (p = 0.047), with predicted serum ORAC scores increasing from the zero dose to a maximum at a 
predicted dose of 4.7 capsules per day and decreasing for higher doses. Among the secondary outcome measures, a 
significant dose effect was observed on phagocytosis of granulocytes, and a significant increase was also observed on 
Cox 2 expression.
Conclusion: This study suggests that Ambrotose AO® capsules appear to be safe and most effective at a dosage of 4 
capsules/day. It is important that this study is not over interpreted; it aimed to find an optimal dose to assess the 
dietary supplement using a more rigorous clinical trial design. The study achieved this aim and demonstrated that the 
dietary supplement has the potential to increase antioxidant activity. The most significant limitation of this study was 
that it was open label Phase 1/Phase 2 trial and is subject to potential bias that is reduced with the use of 
randomization and blinding. To confirm the benefits of this dietary supplement these effects now need to be 
demonstrated in a Phase 3 randomised controlled trial (RCT).
Trial Registration: Australian and New Zealand Clinical Trials Register: ACTRN12605000258651
Background
There is now substantial evidence that reactive oxygen
species (ROS), or oxygen free radicals, are involved in a
range of inflammatory diseases [1-3]. Normally ROS are
effectively detoxified in the body by the presence of scav-
enging substances known as antioxidants and antioxidant
defence enzymes. Oxidative stress occurs when there is
an imbalance between ROS production and the body's
intrinsic scavenging capacity leading to an excess of ROS
[3]. Individuals who are critically ill are generally exposed
to an increase in oxidative stress [4] which has been dem-
onstrated to be proportional to the severity of their con-
dition [5]. One of the reasons that oxidative stress occurs
* Correspondence: smyers@scu.edu.au
1 Australian Centre for Complementary Medicine Education and Research, A 
Joint Venture of the University of Queensland and Southern Cross University, 
Lismore, Australia
Full list of author information is available at the end of the articleBioMed Central
© 2010 Myers et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Myers et al. BMC Complementary and Alternative Medicine 2010, 10:16
http://www.biomedcentral.com/1472-6882/10/16
Page 2 of 16in critical illness, is that the plasma concentrations of
antioxidant micronutrients are low. This occurs as a
result of fluid losses, low nutrient intakes, dilution of
nutrient concentration by resuscitation fluids, and the
redistribution of nutrient from plasma to tissues as part
of the inflammatory process [6,7].
The low plasma concentration of antioxidant nutrients
has led to the postulation that antioxidant therapy may
play a role in the treatment of numerous diseases, ranging
from acute and chronic inflammation to shock and isch-
emia/reperfusion injury [1,2,8,9]. Recent research using
antioxidant therapies has demonstrated positive effects in
both acute[10] and chronic inflammatory conditions [11].
A recent review of the role of oxidative stress-related
organ dysfunction in inflammatory and septic conditions
demonstrated that only three antioxidant nutrients, sele-
nium, glutamine and eicosapentaenoic acid, have demon-
strated clinical benefits and reached the highest level of
evidence [7]. The reviewers concluded that other antioxi-
dants are still awaiting well-designed clinical trials.
A range of foods have been found to contain antioxi-
dant constituents which have been demonstrated to
effect human antioxidant status. These include spinach
[12], strawberries [12], honey [13], soy foods [14] and a
variety of edible nuts including pistachios [15], almonds
[16] and hazelnuts [17]. Phenolic and polyphenolic com-
pounds are responsible for most of the antioxidant capac-
ity found in fruits, vegetables and most botanical
antioxidant supplements [18]. These include quercetin a
dietary flavonoid (a polyphenolic) abundant in onions
[19] and present in a wide variety of fruits and vegetables
and the flavonoid epcatechin found in cocoa, tea and
grapes [20].
This present study tested a dietary supplement contain-
ing a mixture of antioxidant compounds (Vitamin E and
quercetin) and concentrated plant extracts (including
green tea and grape extracts) using an open label forced
titration design to determine both its acute safety and its
antioxidant and immunomodulatory effects in a popula-
tion of healthy smokers and non-smokers. This is a com-
bined Phase 1 and 2 study aimed at determining the
optimal dose to assess in a Phase 3 randomized con-
trolled trial.
Methods
Research Design
The trial was an open label forced titration dose response
study conducted over 5 weeks in healthy smokers and
healthy non-smokers in Lismore, a regional city, in north-
ern New South Wales and was conducted in 2005. In a
forced titration study, the study preparation at different
doses is given to all subjects. In this study the study prep-
aration was given in increasing doses every week over 5
weeks. In order to test the preparation in healthy volun-
teers with a low and high exposure to oxidative stress,
non-smokers and smokers were selected respectively.
The study was approved by two ethical review panels,
the Human Research Ethics Committee of Southern
Cross University (Ethics approval number: ECN-04-156)
and the University of Queensland Human Research Eth-
ics Committee (Ethics approval number: 200400036).
The research was conducted in compliance with Good
Clinical Practices (GCP) and in accordance with the
guidelines of the Australian National Health and Medici-
nal Research Council and the Declaration of Helsinki (as
revised in 2004). The trial was registered with the Austra-
lian and New Zealand Clinical Trials Register
(ACTRN12605000258651).
Participants
A convenience sample healthy individuals, half smokers
and half non-smokers, aged between 18 and 50 years
were recruited by email from staff and students at South-
ern Cross University, and from Lismore, and surrounding
areas through newspaper advertising, regional radio and
television. Individuals were accepted to the study on a
first come basis provided they met the study inclusion
and exclusion criteria. All participants received a study
information sheet outlining the study and signed a con-
sent form agreeing to participate.
A sample size estimate (alpha 0.05 and beta 0.8) based
on pilot data from an open label study conducted by
Mannatech Inc (Coppell, Texas, USA) in healthy non-
smokers required 10 participants to demonstrate changes
in the antioxidant status (the primary outcome). In order
to assess the effectiveness of the preparation in low and
high oxidative stress it was decided to recruit 10 non-
smokers and 10 smokers.
Participants were included if they were healthy, and had
neither an acute or chronic medical condition. This was
determined by a comprehensive general health question-
naire and assessment by the clinical trial nurse (JO), with
any concerns resolved by a medical practitioner (SPM).
Baseline bloods were also reviewed to ensure subjects
with undiagnosed abnormalities were not included. Par-
ticipants were excluded if they were: taking antioxidant
medications and/or other dietary supplements; if they
had poor venous access; if they had a history of any auto-
immune disorders or diabetes; if they were taking
immune suppressant drugs, cytokines, interferon, Echi-
nacea or other immune stimulating herbs; if they had
clinically abnormal liver function tests at baseline; were
unwilling to have blood taken 6 times during the study; or
were unwilling to comply with the study protocols.
Outcome Measurements
The primary outcome measurement was ex vivo changes
in serum oxygen radical absorbance capacity. The sec-
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phocyte subsets [Mature T Cells (CD3+), B Cells
(CD19+), Helper T cells (CD3+CD4+), Cytotoxic T Cells
(CD3+CD8+), Natural Killer (NK) Cells (CD3-
CD16+and/orCD56+)], phagocytosis of granulocytes and
monocytes, natural killer cell cytotoxicity and cyclooxy-
genase-2 (COX-2) expression. These immune indices
were chosen to explore other biological activities that
may be plausibly altered by components within the prep-
aration under investigation.
Two baseline efficacy measurements were taken one
week apart prior to the commencement of study medica-
tion and subsequent measurements were taken weekly
for 4 weeks. Six measurements were taken in total and
participants attended 6 clinics during which weight,
blood pressure and concomitant medication use was
recorded and fasting blood samples collected.
Safety was assessed by actively monitoring adverse
events and by a full blood count, liver function tests and
determination of urea, creatinine and electrolytes taken
at the first baseline measurement and at the conclusion of
the study to assess toxicity to the hemopoietic, hepatic
and renal system. Vital signs (pulse and blood pressure)
and weight were also monitored at every measurement
point.
Subjects returned all remaining capsules at each clinic
and these were counted as a measure of compliance. The
investigator maintained an inventory record of all cap-
sules received and dispensed. It was assumed that cap-
sules not returned were taken.
Study Supplement and Dosing Schedule
The study product Ambrotose AO® capsules was provided
by Mannatech, Incorporated, (Coppell, Texas). The prep-
aration is sold widely in the United States as a dietary
supplement. Each capsule contained 18 mg vitamin E as
mixed tocopherols (as d-alpha, d-beta, d-delta and d-
gamma tocopherols); 113 mg of an antioxidant blend
(quercetin dihydrate; grape skin extract; green tea extract;
Terminalia ferdinandiana [Australian bush plum pow-
der], 331 mg of a proprietary blend of plant polysaccha-
ride and fruits and vegetables powders (aloe vera inner
leaf gel, gum acacia, xanthan gum, gum tragacanth, gum
ghatti, broccoli, brussel sprouts, cabbage, carrot, cauli-
flower, garlic, kale, onion, tomato, turnip, papaya and
pineapple.
The dosing schedule was one capsule daily for one week
after completion of the second baseline measurement. At
the end of first week of supplementation, participants
then commenced on two capsules daily for the second
week, followed by 4 capsules daily for the third week and
eight capsules daily for the fourth week. Measurements
were taken before and after each increase in dosage.
Laboratory Assays
Serum Oxygen Radical Absorbance Capacity (ORAC)
The ORAC assay employed in this study measured the
antioxidant scavenging capacity of serum samples,
against peroxyl radicals induced by 2, 2'-azobis (2-amidi-
nopropane) dihydrochloride (AAPH) (Wako, Richmond,
VA, USA) at 37°C. Fluorescein sodium salt
(C20H12O5·2Na) (Aldrich, St. Louis, MO, USA) was used
as the fluorescent probe. The method is based on that of
Prior et al. [21] for measuring the antioxidant capacity of
plasma and other biological samples.
Sample Preparation
Serum samples were stored at -80°C until analysis. Sam-
ples were thawed to room temperature, mixed by vortex,
and then centrifuged (3 min. at 13 000 g). Serum (100 μL)
was added to a 1.5 mL micro centrifuge tube with 300 μL
Milli-Q water and 400 μL 0.5 M perchloric acid (Sigma,
St. Louis, MO, USA), giving a 1 in 8 dilution. Samples
were mixed by vortexing, centrifuged (5 min. at 13 000 g),
and the supernatant was serially diluted 1 in 2 with 75
mM phosphate buffer, pH7.4 (Sigma, St. Louis, MO,
USA), giving a dilution series of 1 in 8, 1 in 16, 1 in 32,
and 1 in 64. Each dilution was assayed in triplicate.
Method
Trolox ((±)-6-Hydroxy-2,5,7,8-tetra-methylchromane-2-
carboxylic acid) (Fluka, Buchs, Switzerland), a water solu-
ble analogue of vitamin E, was used as a reference stan-
dard. A working Trolox solution (10 μL stock solution,
990 μL perchloric acid precipitating solution) was pre-
pared from a Trolox stock solution (0.01 M, in 75 mM
phosphate buffer, pH 7.4). The working solution was then
serially diluted 1 in 2 with phosphate buffer (75 mM,
pH7.4). A standard curve was established from Trolox
standards prepared at 100, 50, 25, and 12.5 μM.
Grape juice (commercially available from supermarket)
was included as a control, and was diluted similarly, firstly
with perchloric acid precipitating solution, and then seri-
ally diluted with phosphate buffer (75 mM, pH 7.4), giv-
ing final concentrations of 20, 10, 5, and 2.5 μL/mL.
Briefly, 10 μL fluorescein (6.0 × 10-7M), 20 μL samples/
standards/control/blank (perchloric precipitating solu-
tion) and 170 μL AAPH (20 mM) were added per well.
Immediately after loading, the 96 well black fluorescence
plate (Greiner, Frickenhausen, Germany) was transferred
to the Wallac Victor2 plate reader, preset to heat to 37°C,
and the fluorescence was measured every minute for 35
minutes. The fluorescence readings were referenced to
solvent blank wells. The final serum ORAC values were
calculated using linear regression between the Trolox
concentration and the net area under the fluorescein
decay curve, and were expressed as micromole Trolox
equivalents (TE) per litre of serum.
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Flow cytometric analysis was used for monitoring the
expression of CD3+, CD4+, CD8+, CD19+, CD16+ &
CD56+ antigens on peripheral blood lymphocytes (PBL).
Staining of PBL was performed by the BD Lyse/No Wash
method using MultiTEST IMK kit reagents (BD Biosci-
ences, San Jose, CA, USA).
Briefly, 50 μl whole blood (EDTA) was added to 20 μl of
both monoclonal antibodies (CD3/CD8/CD45/CD4 &
CD3/CD16+56/CD45/CD19). Tubes were vortexed and
incubated for 15 minutes in the dark at room tempera-
ture. 450 μl 1× MultiTEST Lysing Solution (BD Biosci-
ences, San Jose, CA, USA). was added to each tube, then
tubes were vortexed and incubated for 15 minutes in the
dark at room temperature. The samples were then analy-
sed on a BD FACSCalibur flow cytometer, with BD Mul-
tiSET software, using excitation wavelengths of 488 nm &
635 nm.
Absolute white blood cell (WBC) and lymphocyte per-
centage values, obtained from a Beckman Coulter AcT
Diff analyser, were used for lymphocyte subset calcula-
tions.
Phagocytic Activity
Blood samples were assayed for both granulocyte &
monocyte phagocytic activity (post E. coli stimulation) by
flow cytometry using the Phagotest kit (Orpegen
Pharma, Heidelberg, Germany).
E. coli, commercially labelled with fluorescein isothio-
cyanate (FITC) (Orpegen Pharma, Heidelberg, Ger-
many), was added to aliquots of blood from each lithium
heparinised blood sample and incubated for 10 minutes
at 37°C. Baseline controls (0°C) were also run for each
sample. For each aliquot, the percentage of phagocytes
(granulocytes & monocytes) that had ingested the FITC
labelled bacteria (E. coli) was then determined by flow
cytometry using a BD FACSCalibur instrument.
NK Cell Cytotoxic Activity
Peripheral blood mononuclear cells (PBMC) were pre-
pared from each lithium heparinised blood sample using
Ficoll-Paque (Amersham Biosciences, Piscataway, New
Jersey, USA). K562 cells, an erythroblastic leukaemia cell
line (ATCC, Manassas, VA, USA) susceptible to NK cell
cytotoxic activity, were pre-labelled with a green fluores-
cent dye, DiO (Molecular Probes, Carlsbad, CA, USA).
The PBMCs for each sample were incubated for two
hours (37°C) with the K562 target cells at a ratio of 25:1
(PBMC:K562). After incubation, a cell viability dye, pro-
pidium iodide (Molecular Probes, Carlsbad, CA, USA),
was added to label the K562 target cells permeabilised by
NK activity. A target cell control was also run to monitor
spontaneous K562 death. The percentage of dead target
cells for each sample was determined by flow cytometry
using a BD FACSCalibur instrument. Specific NK cell
cytotoxicity was determined as the difference between
the percent dead K562 for each test sample and the target
cell control. This method is based on that outlined in the
NKTest Protocol (Orpegen Pharma).
Cox-2 Expression
Blood samples were assayed for monocyte Cox-2 expres-
sion post stimulation with E. coli lipopolysaccharide
(LPS) (Sigma, St. Louis, MO, USA).
LPS (final concentration 0.01 μg/mL) was added to ali-
quots of blood from each lithium heparinised blood sam-
ple and incubated for two hours at 37°C. Baseline controls
(no LPS) were also run for each sample. Samples from
each aliquot were then stained with fluorochrome
labelled monoclonal antibodies (mAbs) CD14-PerCP (BD
Biosciences, San Jose, CA, USA) then intracellularly with
Cox-2-PE (BD Biosciences, San Jose, CA, USA). The per-
centage of monocytes expressing Cox-2 was then deter-
mined by flow cytometry using a Becton Dickinson
FACSCalibur instrument. This method is based on that of
Ruitenberg and Waters [22].
Results
Study Participants
The study screened 30 individuals by phone resulting in
24 clinic appointments. Subsequently 22 individuals were
enrolled in the study. One participant (47 year old male)
did not show after week 3 and was lost to follow up. One
subject (43 year old female) was withdrawn at week 5
with diarrhoeal complaint, and one subject (37 year old
female) was withdrawn at week 6 with an upper respira-
tory tract infection. Twenty one (n = 21) data sets were
analysed, comprising 9 non-smokers (3 males, 6 females)
and 13 smokers (5 males, 8 females). The mean age (±
SD) of the participants was 41 years (± 8.55) with a
median age of 43.5 years (range 21 - 50 years). The mean
age (± SD) of the non-smokers was 42 years (± 7.75) with
a median age of 44 years (range 27 - 50 years). The mean
age (± SD) of the smokers was 39.5 years (± 9.58) with a
median age of 43 years (range 21 - 50 yrs).
Antioxidant Activity
Descriptive statistics including sample size, mean, stan-
dard deviation, minima and maxima for the primary out-
come measures of Oxygen Radical Absorption Capacity
(serum ORAC) are reported in Table 1 by dosage level,
gender and smoking status. Figure 1 graphically repre-
sents these finding for serum ORAC by gender and smok-
ing status.
General linear mixed models (SPSS Mixed) with
repeated measures were fitted to the data to maximise
retention of data on subjects with missed occasions of
measurement. Optimal variance-covariance structures
(compound symmetry) were fitted to adjust the estimates
and their standard errors for the dependency arising from
repeated measurements on the same subjects.
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The response over doses formed a consistent pattern for
female smokers and non-smokers and male non-smokers.
Relative to this typical pattern, a number of anomalies
were observed in the male smoker data. These data were
excluded from further analyses so that models could be
focused on estimating the typical response profile.
Two different types of models were fitted to the data.
The first treated all effects, group (3 levels - male non-
smoker, female non smoker and female smoker) and dose
(5 levels) as factors (effects model). The second fitted
dose response models that treated group as a factor but
dose as a linear (0, 1, 2, 4, 8) component and dose squared
(0, 1, 4, 16, 64) as a quadratic component. Dose response
models always retained linear and quadratic dose effects
even if non significant.
Full models were initially fitted and appropriate non-
significant factors were eliminated. All models were fitted
as restricted maximum likelihood mixed models with
hierarchical decomposition (Type 1) using covariance
structures as specified.
The full factorial model is reported in Table 2 and
included all main effects (group and dose) and the group
by dose interaction, and the main effects only model for
serum ORAC together with degrees of freedom and p
values. There was a significant dose effect (p = 0.040) for
the serum ORAC primary outcome.
Estimated Means and standard errors for dose levels for
serum ORAC and p values for Bonferroni adjusted post
hoc comparisons with baseline means presented in Table
3. The predicted means (± SE) by dose are presented in
Figure 2.
There were significant increases in serum ORAC levels
from baseline (mean 376.4) in the dose of 4 capsules per
day (mean 514.0) p ≤ 0.010, an increase in means of
36.5%. Note that male smokers were not included in these
analyses.
ORAC Dose response models
Progressively fitted models for serum ORAC are reported
in Table 4. There was no significant interaction and no
significant group effect for the serum ORAC primary
Table 1: Means (± SD), minima and maxima for serum ORAC by gender and smoking status.
Non Smoker Smoker
N Mean SD Min Max N Mean SD Min Max
ORAC Male Baseline 1 5 428 115 310 562 3 510 100 439 581
Baseline 2 5 391 145 239 577 3 157 42 122 204
Dose 1 5 389 267 116 728 3 757 145 669 924
Dose 2 5 397 196 167 645 3 643 89 576 744
Dose 4 5 649 164 510 885 3 309 183 176 518
Dose 8 5 536 202 243 707 3 626 38 591 667
Female Baseline 1 8 352 140 111 535 6 534 65 423 587
Baseline 2 8 311 122 135 447 6 287 91 156 429
Dose 1 8 407 170 71 623 6 460 231 192 849
Dose 2 8 372 200 122 774 6 396 186 169 626
Dose 4 8 466 153 263 672 6 460 104 340 615
Dose 8 8 382 132 169 577 6 292 169 130 499
All Baseline 1 13 380 131 111 562 9 527 68 423 587
Baseline 2 13 337 129 135 577 9 244 99 122 429
Dose 1 13 401 195 71 728 9 559 246 192 924
Dose 2 13 380 190 122 774 9 478 197 169 744
Dose 4 13 527 174 263 885 9 410 144 176 615
Dose 8 13 438 170 169 707 9 435 216 130 667
Baseline 1 and 2 were taken prior to the administration of study preparation.
Dose 1 = 1 capsule daily for one week; Dose 2 = 2 capsules daily for one week;
Dose 3 = 4 capsules daily for one week; and Dose 4 = 8 capsules daily for one week.
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Figure 1 Serum ORAC - Plots of Means (± SE) by gender and smoking status for each dose. Baseline 1 and 2 were taken prior to the administra-
tion of study preparation.
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Page 7 of 16outcome. In the final model (Model 3) with any interac-
tions and the group effect eliminated, the quadratic dose
effect was significant p ≤ 0.047. The regression parame-
ters results of the final model (Model 3) are reported in
Table 5. By differentiating the quadratic equation and
equating the derivative to zero, a maximum or minimum
dose can be determined. The quadratic equation for
serum ORAC is Y = 373.4 + 46.5 * dose - 4.9 * dose * dose.
Therefore, dy/dx = 46.5 - 4.9 * 2 *dose. By equating dy/dx
= 0 enables one to solve the equation dose = -46.5/(-
4.9*2). Therefore, the optimal estimated dose is 4.7 cap-
sules per day.
Immune Function
The secondary outcome measures of immune function
were 1) mature t cell numbers; 2) mature b cell numbers;
3) helper t cell numbers; 4) suppressant t cell numbers; 5)
natural killer cell numbers; 6) phagocytosis of granulo-
cytes; 7) phagocytosis of monocytes; 8) natural killer cell
cytotoxicity; and 9) cox 2 expression. Descriptive statis-
tics including sample size, mean, standard deviation,
minima and maxima for these outcome measures are
reported in Table 6 by dosage level, gender and smoking
status.
General linear mixed models (SPSS Mixed) with
repeated measures were fitted to the data to ensure maxi-
mise retention of data on subjects with missed occasions
of measurement. Optimal variance-covariance struc-
tures (compound symmetry or completely general or
unstructured) were fitted to adjust the estimates and their
standard errors for the dependency arising from repeated
measurements on the same subjects.
The main effects factorial model (smoker, gender and
dose) for all secondary outcome measures together with
degrees of freedom and p values is reported in Table 7.
All 2 way and 3 way interactions were non significant.
Hierarchical method of fitting was used so that measure-
ments were adjusted for smoking status, and gender
before the dose factor was fitted.
The fitting of the factorial models resulted in significant
smoking status factor for mature b cell numbers (p ≤
0.028), natural killer cell numbers (p ≤ 0.003) and urinary
creatinine (p ≤ 0.029); significant gender factor for phago-
cytosis of granulocytes (p ≤ 0.035), phagocytosis of
monocytes (p ≤ 0.007) and natural killer cell activity (p ≤
0.040); and significant dose factor for phagocytosis of
granulocytes (p ≤ 0.000), phagocytosis of monocytes (p ≤
0.003) and cox 2 expression (p ≤ 0.001).
The assays for phagocytosis of granulocytes and mono-
cytes were handled by a single operator for all measure-
ments excepting week 4. As these measurements are
sensitive to laboratory operator variation it was decided
by the study team to undertake separate analysis with the
dose of 4 capsules per day excluded. Under these condi-
tions there was a significant dose effect retained for
phagocytosis of granulocytes only (p ≤ 0.000).
The significant effects together with estimated mar-
ginal means, standard errors and significant post hoc
comparisons (Bonferroni adjusted) for secondary out-
come variables is reported in Table 8. The two variables
which had a significant dose effect, phagocytosis of gran-
ulocytes (with 4 capsule dose excluded) and cox 2 expres-
sion are shown in Figure 3.
Table 2: The effects models for serum ORAC with p values (hierarchical method).
P values
Effect df Full Factorial Model Main Effects Model
Intercept 1 0.000 0.000
Group 2 0.350 0.358
Dose 4 0.043 0.040
Group * dose 8 0.492
Table 3: Serum ORAC estimated means (± SE) and p values for post-hoc comparisons (male smokers excluded).
Dose Mean SE p value for comparison with baseline
Baseline 376.42 31.50
1 430.15 39.79 0.898
2 395.15 39.79 1.000
4 514.04 39.79 0.010
8 405.71 43.09 1.000
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Participants report of adverse events treated with permit-
ted medication (paracetamol/acetaminophen) included,
headache (n = 6), sports related pain (n = 1), and period
pain (n = -1). Three participants reported the following
adverse events but did not use medication, removal of
basal cell carcinoma from the right cheek (n = 1), prepa-
ratory injections for overseas travel (hepatitis A and
typhoid) (n = 1), flatulence and constipation (n = 1). One
subject (35 year old female) treated a cold sore with L-
lysine 500 mgs over 4 days during week 4.
Repeated measures analyses using SPSS GLM was used
to analyse the baseline and final scores for safety mea-
sures for the full factorial model of smoking status, gen-
der and smoking status by gender interaction. Post-hoc
comparisons of baseline measurement versus final mea-
surement for any safety variable showing a significant
effect was undertaken. There were some significant
changes in the safety variables (full blood count, liver
function, urea, creatinine and electrolytes) over the
course of the trial but these were generally small, well
within clinical reference ranges and assessed as not of
clinical significance. These were 1) a decrease in platelet
count in all subjects (normal adult reference range: 150-
400 × 109/L) from an estimated marginal mean of 272.68
to 250.82 (p ≤ 0.005); 2) a decrease in serum potassium in
all subjects (normal adult reference range: 3.8-4.9 mmol/
L) from 4.46 to 4.26 (p ≤ 0.011); 3) an increase in white
cell count in female smokers (normal adult reference
range: 4.0-10.0 × 109/L) from 7.40 to 8.42 (p ≤ 0.048); and
4) an increase in alkaline phosphatase (ALP) in male non-
smokers (normal adult reference range: 47-136 u/L) from
65.60 to 71.80 (p ≤ 0.050).
A similar analysis was undertaken for vital signs (pulse,
systolic and diastolic blood pressure and weight using a
main effects factorial model (smoker, gender and dose).
Hierarchical method of fitting was used so that measure-
ments were adjusted for smoking status, and gender prior
to dose being fitted.
This showed a significant gender factor for systolic
blood pressure (p ≤ 0.050) and significant dose factor for
both weight (p ≤ 0.003) and systolic blood pressure (p ≤
0.022). Mean weight reduction of 0.8 kg was observed
over the 4-week treatment period. The weight reduction
was found not to differ significantly between males and
females. Similarly a decrease in mean systolic blood pres-
sure (121 down to 117 mmHg) was also observed. The
reduction in systolic blood pressure was also found not to
differ significantly between males and females.
Discussion
A significant increase in antioxidant activity (serum
ORAC) was observed between a dose of zero to a dose of
4 capsules per day (p ≤ 0.040). Whilst the observed levels
of serum ORAC differed between groups defined in
terms of gender and smoking status, the extent of the
increase did not differ significantly among these groups
(p ≤ 0.492). The percentage increase in the serum ORAC
mean from baseline to 4 capsules daily was 36.6%. Given
the effect was only seen in both genders in non-smokers
further investigation needs to be in this cohort.
A quadratic function for dose levels was fitted in order
to estimate a dose response curve for estimating the opti-
mal dose. The quadratic component of the curve was sig-
nificant (p = 0.047), with predicted serum ORAC scores
increasing from the zero dose to a maximum at a pre-
dicted dose of 4.7 capsules per day and decreasing for
Figure 2 Serum ORAC predicted means (± SE) by dose(male 
smokers excluded). 
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Table 4: Progressively fitted models for serum ORAC with p values (hierarchical method) [male smokers excluded].
Effect df Model 1 Model 2 Model 3
Intercept 1 0.000 0.000 0.000
Group 1 0.206 0.096
Linear dose 1 0.158 0.153 0.135
Quadratic dose 1 0.047 0.045 0.047
Linear dose * Group 1 0.210
Quadratic dose * Group 1 0.959
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Page 9 of 16higher doses. This suggests that the optimal dose to
assess in a Phase 3 randomized controlled trial is 4 cap-
sules daily.
A few studies have investigated the effects of dietary
changes via foods or supplements on serum ORAC. In
food studies, increases in serum ORAC have been docu-
mented following ingestion of strawberries (14.4%
increase) and spinach (28.5% increase)[12], buckwheat
honey (7% increase) [13] and concord grape juice (8%
increase) [23]. Ingestion of a high-carotenoid content diet
had no effect on serum ORAC [24].
The results of dietary supplementation trials on effect-
ing serum antioxidant status have been mixed. In a pla-
cebo-controlled trial of healthy adults, a single 100 g dose
of wild blueberry powder significantly increased serum
ORAC by up to 16% [25] and a single 1.25 g dose of vita-
min C raised serum ORAC by 23% [12]. In a second pla-
cebo-controlled study of 500 mg/day vitamin C, serum
ORAC was significantly increased, but the percent
change was not indicated [26]. Additional studies of sup-
plements designed to have antioxidant benefits have
demonstrated no effect on serum ORAC: an antioxidant
supplement (vitamin E, beta-carotene, ascorbic acid, sele-
nium, alpha-lipoic acid, N-acetyl 1-cysteine, catechin,
lutein, and lycopene) [27]; either of two antioxidant sup-
plements (an antioxidant vitamin/mineral table or a vita-
min/mineral/fruit and vegetable powder capsule) [24]; or
a fruit-based antioxidant drink (MonaVie Active, Salt
Lake City, Utah) [28]. The Ambrotose AO capsules in this
study which increase serum ORAC by 36% appears to be
the most promising antioxidant supplement investigated
to date, providing more protection than spinach or high
dose vitamin C.
Among the secondary outcome measures, a significant
dose effect was observed on phagocytosis of granulo-
cytes, with the increase being significant from a zero dose
to dose of 8 capsules per day. Due to laboratory operator
variation, the data for dose 4 were deemed to be inconsis-
tent with the remaining data and excluded from analysis.
It was not possible therefore to determine whether there
was a significant increase at a dose of less than 8 capsules
per day. This represents a 12% increase from baseline and
suggests that the preparation may have an immunomod-
ulatory effect by improving the non-specific, anti-infec-
tive mechanisms of defence. The study was not powered
for measuring the secondary outcomes which were
exploratory in nature and the fact that there was no
change in the lymphocyte subset counts or in the other
two markers of non-specific immune response, phagocy-
tosis by monocytes or in natural killer cell cytotoxicity
may be a type II error and these results, therefore, cannot
be considered conclusive.
A significant increase was also observed on Cox 2
expression between a zero dose and a dose of 1 capsule
per day, with Cox 2 expression decreasing from this high
point at higher doses but remaining above the zero dose
level though none of the other comparisons were signifi-
cant. The inducible form of cyclooxygenase, COX-2, is an
immediate-early response gene with complex regulation
that plays an essential role in vascular homeostasis and
inflammation. Pharmacological manipulation of COX-2
activity can have both beneficial and problematic clinical
effects depending on the substrates available in the cell
membrane [29], though the increase of 4% seen in this
study is unlikely to be of any clinical significance.
The preparation was demonstrated to be safe over the
course of the study. Adverse events experienced during
were mild and self limiting, there were no changes in the
haemopoietic, liver or renal systems of clinical signifi-
cance and the vital signs remained healthy. Unanticipated
changes in systolic blood pressure and weight moved in a
generally beneficial direction but were not of any real
clinical significance.
The most significant limitation of this study was that it
was open label combined Phase 1 and 2 trial and is sub-
ject to potential bias that is reduced with the use of ran-
domization and blinding.
Conclusion
It is important that this study is not over interpreted; it
aimed to find an optimal dose to assess the study medica-
tion using a more rigorous clinical trial design. The study
achieved this aim and demonstrated that the study medi-
cation has the potential to increase antioxidant activity in
non-smokers. These activities now need to be demon-
Table 5: Results for quadratic regression model 3 for serum ORAC.
95% C I
Parameter Estimate SE df t Sig. Lower Bound Upper Bound
316.9 429.9
DOSE 46.54 19.71 97.2 2.36 0.020 7.4 85.7
DOSE_SQ -4.89 2.43 97.5 -2.01 0.047 -9.7 -0.06
rMean SD Min Max
2.18 0.62 1.74 2.62
1.75 0.07 1.68 1.82
1.97 0.28 1.69 2.25
1.81 0.16 1.63 1.94
1.93 0.25 1.64 2.12
2.20 0.39 1.84 2.62
2.01 0.68 0.97 2.76
2.01 0.70 0.95 2.98
1.99 0.74 0.80 2.75
1.99 0.67 0.86 2.76
1.99 0.77 0.89 2.97
1.85 0.74 1.11 2.87
0.50 0.15 0.39 0.60
0.37 0.16 0.26 0.55
0.39 0.11 0.32 0.52
0.36 0.14 0.27 0.52
0.36 0.15 0.27 0.53
0.42 0.18 0.29 0.63
0.39 0.17 0.23 0.59
0.32 0.16 0.11 0.53
0.32 0.13 0.14 0.50
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Table 6: Immune function means (± SD), minima and maxima by dosage level, gender and smoking status.
Secondary 
Outcome 
Measures
Non Smoker Smoke
N Mean SD Min Max N
Mature t cell 
Number
Male Baseline 1 5 1.52 0.31 1.10 1.77 3
Baseline 2 5 1.56 0.31 1.19 1.99 3
Dose 1 5 1.56 0.29 1.23 1.82 3
Dose 2 5 1.50 0.40 1.12 1.99 3
Dose 4 5 1.56 0.56 1.11 2.31 3
Dose 8 5 1.65 0.54 1.21 2.37 3
Female Baseline 1 8 1.56 0.46 1.00 2.17 6
Baseline 2 8 1.59 0.34 1.09 1.99 6
Dose 1 8 1.56 0.29 1.07 1.93 6
Dose 2 8 1.68 0.39 0.99 2.12 6
Dose 4 8 1.55 0.35 0.95 1.97 6
Dose 8 8 1.63 0.46 1.02 2.26 6
Mature b cell 
number
Male Baseline 1 5 0.24 0.08 0.17 0.36 3
Baseline 2 5 0.22 0.06 0.16 0.31 3
Dose 1 5 0.25 0.10 0.14 0.36 3
Dose 2 5 0.22 0.06 0.14 0.28 3
Dose 4 5 0.22 0.06 0.15 0.30 3
Dose 8 5 0.22 0.05 0.19 0.30 3
Female Baseline 1 8 0.24 0.05 0.17 0.34 6
Baseline 2 8 0.24 0.05 0.16 0.29 6
Dose 1 8 0.25 0.08 0.15 0.37 6
Dose 2 8 0.26 0.08 0.16 0.38 6M
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w Dose 4 8 0.24 0.06 0.15 0.34 6 0.35 0.20 0.11 0.60
Dose 8 8 0.25 0.05 0.18 0.30 6 0.34 0.17 0.12 0.49
1.27 0.18 1.14 1.40
1.19 0.31 0.88 1.50
1.32 0.23 1.13 1.58
1.21 0.28 0.99 1.53
1.29 0.37 1.06 1.71
1.53 0.53 1.22 2.14
1.24 0.39 0.60 1.61
1.24 0.38 0.61 1.59
1.24 0.46 0.52 1.83
1.23 0.39 0.56 1.75
1.25 0.49 0.59 2.06
1.10 0.29 0.75 1.44
0.77 0.54 0.39 1.15
0.54 0.25 0.38 0.83
0.61 0.31 0.42 0.96
0.55 0.23 0.37 0.81
0.59 0.26 0.43 0.89
0.63 0.18 0.49 0.84
0.77 0.43 0.36 1.50
0.74 0.45 0.33 1.62
0.72 0.42 0.27 1.50
0.72 0.42 0.29 1.51
0.73 0.41 0.29 1.45
0.77 0.54 0.33 1.55
0.36 0.02 0.34 0.37
0.27 0.04 0.24 0.31
0.29 0.02 0.28 0.32
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Helper t cell 
number
Male Baseline 1 5 0.99 0.30 0.58 1.23 3
Baseline 2 5 0.98 0.31 0.69 1.40 3
Dose 1 5 1.01 0.31 0.59 1.28 3
Dose 2 5 0.99 0.39 0.63 1.43 3
Dose 4 5 1.02 0.47 0.58 1.61 3
Dose 8 5 1.09 0.52 0.64 1.76 3
Female Baseline 1 8 0.96 0.29 0.70 1.46 6
Baseline 2 8 1.00 0.22 0.73 1.29 6
Dose 1 8 0.97 0.15 0.73 1.20 6
Dose 2 8 1.06 0.23 0.66 1.33 6
Dose 4 8 0.98 0.21 0.62 1.18 6
Dose 8 8 1.02 0.27 0.61 1.29 6
Suppressant t 
cell number
Male Baseline 1 5 0.47 0.12 0.28 0.59 3
Baseline 2 5 0.54 0.19 0.28 0.81 3
Dose 1 5 0.51 0.17 0.27 0.75 3
Dose 2 5 0.50 0.17 0.31 0.70 3
Dose 4 5 0.52 0.19 0.29 0.72 3
Dose 8 5 0.53 0.17 0.31 0.66 3
Female Baseline 1 8 0.55 0.20 0.30 0.89 6
Baseline 2 8 0.53 0.16 0.31 0.80 6
Dose 1 8 0.54 0.15 0.34 0.79 6
Dose 2 8 0.55 0.19 0.30 0.86 6
Dose 4 8 0.53 0.16 0.32 0.81 6
Dose 8 8 0.56 0.24 0.31 0.98 6
Natural killer 
cell number
Male Baseline 1 5 0.20 0.14 0.08 0.44 3
Baseline 2 5 0.22 0.16 0.12 0.50 3
Dose 1 5 0.19 0.13 0.11 0.41 3
Table 6: Immune function means (± SD), minima and maxima by dosage level, gender and smoking status. (Cont
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0.30 0.03 0.27 0.32
0.34 0.12 0.26 0.48
0.21 0.12 0.12 0.41
0.25 0.15 0.10 0.50
0.21 0.09 0.12 0.37
0.24 0.12 0.11 0.45
0.25 0.09 0.14 0.37
0.32 0.18 0.14 0.56
40.6 1.3 39.6 41.5
40.4 8.4 31.0 47.2
48.0 4.9 42.4 51.6
49.2 15.0 32.8 62.2
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48.1 5.5 43.7 54.2
40.0 8.8 27.1 49.3
53.8 8.0 46.0 65.2
46.3 9.0 32.9 57.9
51.4 13.8 28.6 65.9
48.5 8.8 36.2 58.6
56.3 6.7 47.0 61.9
29.1 3.5 26.6 31.5
30.4 9.4 23.9 41.2
35.3 3.1 31.9 38.0
35.4 10.1 25.8 46.0
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32.4 5.1 25.3 39.2
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Dose 4 5 0.16 0.06 0.10 0.21 3
Dose 8 5 0.17 0.08 0.07 0.24 3
Female Baseline 1 8 0.18 0.08 0.10 0.32 6
Baseline 2 8 0.18 0.06 0.10 0.28 6
Dose 1 8 0.19 0.08 0.10 0.35 6
Dose 2 8 0.20 0.07 0.11 0.29 6
Dose 4 8 0.17 0.06 0.10 0.26 6
Dose 8 8 0.18 0.09 0.09 0.31 6
Phagocytosis 
of 
Granulocytes
Male Baseline 1 5 37.1 6.0 31.0 44.4 3
Baseline 2 5 47.6 5.1 39.6 53.2 3
Dose 1 5 35.4 3.1 33.0 39.8 3
Dose 2 5 48.8 14.3 27.5 58.1 3
Dose 4 5 40.4 6.3 30.9 44.5 3
Dose 8 5 48.6 3.4 44.5 51.5 3
Female Baseline 1 8 38.8 10.1 27.6 57.3 6
Baseline 2 8 51.4 7.4 37.6 60.7 6
Dose 1 8 49.3 13.3 33.3 75.7 6
Dose 2 8 46.0 13.9 26.6 64.2 6
Dose 4 8 39.5 7.3 34.8 51.7 6
Dose 8 8 50.9 8.9 39.5 63.7 6
Phagocytosis 
of monocytes
Male Baseline 1 5 31.1 4.5 24.9 35.6 3
Baseline 2 5 35.5 2.2 33.3 38.9 3
Dose 1 5 27.1 3.2 23.5 32.0 3
Dose 2 5 38.4 10.8 22.5 45.7 3
Dose 4 5 31.8 5.7 25.1 37.6 3
Dose 8 5 37.6 1.8 35.8 39.7 3
Female Baseline 1 8 34.7 8.4 20.0 47.3 6
Table 6: Immune function means (± SD), minima and maxima by dosage level, gender and smoking status. (Continu
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83.7 4.8 78.4 92.3
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Dose 2 8 33.1 7.3 22.5 45.3 6
Dose 4 8 30.9 4.6 25.0 38.6 6
Dose 8 8 32.5 5.5 24.0 39.9 6
Natural killer 
cell 
cytotoxicity
Male Baseline 1 5 15.5 6.0 10.6 25.2 3
Baseline 2 5 18.7 5.4 11.0 25.4 3
Dose 1 5 18.1 6.8 10.4 24.8 3
Dose 2 5 13.7 4.8 7.5 19.3 3
Dose 4 5 14.1 4.1 8.9 19.0 3
Dose 8 5 15.1 2.8 11.3 17.8 3
Female Baseline 1 8 14.8 5.9 9.1 24.0 6
Baseline 2 8 13.9 5.7 8.7 25.6 6
Dose 1 8 15.0 5.3 8.9 24.6 6
Dose 2 8 14.1 5.2 8.6 21.6 6
Dose 4 8 13.4 4.3 7.6 19.1 6
Dose 8 8 12.5 5.0 7.8 19.1 6
Cox 2 Male Baseline 1 5 78.0 8.9 67.8 89.6 3
Baseline 2 5 82.9 2.9 79.7 85.3 3
Dose 1 5 82.6 3.1 79.0 86.4 3
Dose 2 5 83.2 1.4 82.2 85.3 3
Dose 4 5 78.2 5.1 73.8 85.2 3
Dose 8 5 79.4 3.6 75.4 83.5 3
Female Baseline 1 8 78.9 5.9 71.8 87.9 6
Baseline 2 8 81.0 5.5 72.0 88.5 6
Dose 1 8 82.6 3.5 75.9 88.0 6
Dose 2 8 83.6 3.8 77.3 89.2 6
Dose 4 8 81.0 4.3 73.4 85.2 6
Dose 8 8 81.3 5.2 76.1 90.1 6
Baseline 1 and 2 were taken prior to the administration of study preparation.
Table 6: Immune function means (± SD), minima and maxima by dosage level, gender and smoking status. (Continu
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Table 7: Immune Function p values for the main effects factorial models.
Secondary Outcome Measures Smoking status Gender Dose
Mature t cell number 0.053 0.901 0.320
Mature b cell number 0.029 0.704 0.839
Helper t cell number * 0.093 0.824 0.134
Suppressant t cell number 0.188 0.565 0.806
Natural killer cell number* 0.004 0.165 0.179
Phagocytosis of granulocytes* 0.389 0.036 0.000
(4 capsule dose excluded) 0.607 0.038 0.000
Phagocytosis of monocytes * 0.872 0.007 0.003
(4 capsule dose excluded) 0.516 0.020 0.094
Natural killer cell activity 0.129 0.040 0.345
Cox 2 inhibition * 0.937 0.630 0.001
* indicates models were fitted with unstructured variance-covariance otherwise compound symmetry models were fitted.Table 8: Immune Function significant effects exist and significant post hoc comparisons.
Secondary Outcome Measure Effect Mean SE Pairwise p value
Mature B Cell Number Smoker No 0.25 0.03 0.028
Yes 0.35 0.04
Natural Killer Cell Number Smoker No 0.20 0.02 0.003
Yes 0.27 0.02
Phagocytosis of Granulocytes Dose Baseline 45.01 1.43 base vs 8 0.002
1 43.70 2.17 1 vs 8 0.038
2 50.68 2.89 2 vs 4 0.010
4 42.81 1.65 4 vs 8 0.000
8 50.49 1.58
Gender Male 43.70 2.18 0.038
Female 49.37 1.73
Phagocytosis of Granulocytes Dose Baseline 45.01 1.44 base vs 8 0.001
(4 capsule dose excluded) 1 43.96 2.19 1 vs 8 0.026
2 50.36 2.92
8 50.47 1.54
Gender Male 44.64 2.23 0.035
Female 50.27 1.78
Phagocytosis of Monocytes Dose Baseline 34.37 0.89 2 vs 4 0.003
1 33.24 1.38
2 35.76 1.83
4 32.01 1.27
8 32.70 1.41
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Page 15 of 16strated in a Phase 3 randomised double-blind placebo-
controlled trial in non-smokers (RCT).
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Gender Male 31.43 1.29 0.007
Female 35.80 1.02
Phagocytosis of Monocytes Gender Male 32.03 1.39 0.022
(4 capsule dose excluded) Female 35.93 1.09
Natural Killer Cell Cytotoxicity Gender Male 19.41 1.70 0.04
Female 14.77 1.28
Cox 2. Dose Baseline 80.42 1.06 base vs 1 0.047
1 83.77 0.79
2 81.99 0.73
4 81.69 1.07
8 81.80 1.26
Table 8: Immune Function significant effects exist and significant post hoc comparisons. (Continued)
Figure 3 Immune function variables with a significant dose effect. 
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